SodiUm SeleniTe Adminstration IN Cardiac Surgery (SUSTAIN CSX®-Trial). (SUSTAINCSX)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02002247|
Recruitment Status : Recruiting
First Posted : December 5, 2013
Last Update Posted : February 27, 2018
|Condition or disease||Intervention/treatment||Phase|
|Heart Disease||Drug: sodium selenite Drug: Placebo||Phase 3|
Over a million patients undergo open heart surgery annually and this number is likely to accelerate as the population ages and the prevalence of diabetes and cardiovascular disease continue to increase. Unfortunately, death, organ failure, and other serious complications are all too frequent following open heart surgery, especially in some high-risk patient populations.
Selenium is a trace element that is important for many of the body's regulatory and metabolic functions especially during times of stress. International members of the study team have shown in a non-randomized study that high dose selenium supplementation was associated with improved clinical outcomes compared to a historical control group. The next step in this program of research is to conduct a randomized trial.
The aim of this research program is to investigate the effects of perioperative high dose selenium supplementation in high-risk cardiac surgical patients undergoing complicated open heart surgery. The investigators hypothesize that the therapeutic strategy tested in this randomized trial may contribute to fewer complications, less organ injury and fewer deaths.
The investigators propose to conduct a randomized, placebo-controlled, double-blind, multicentre definitive trial of 1400 patients across 20 sites in Germany and Canada, which will include the pilot study patients. An industry partner (Biosyn) will provide the product and some additional support for the European sites. Patients will be randomized to receive either a daily perioperative high-dose selenium or placebo until postoperative day 10 (maximum) or upon earlier discharge from ICU. If the hypothesis is proven true, and this simple, inexpensive nutrient reduces complications and improves recovery of patients undergoing cardiac surgery, there is the potential to dramatically change clinical practice and improve health outcomes.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||1400 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||SodiUm SeleniTe Adminstration IN Cardiac Surgery (SUSTAIN CSX®-Trial). A Multicentre Randomized Controlled Trial of High Dose Sodium-selenite Administration in High Risk Cardiac Surgical Patients|
|Study Start Date :||January 2015|
|Estimated Primary Completion Date :||December 2019|
|Estimated Study Completion Date :||June 2020|
Placebo Comparator: Placebo
Normal saline will be administered to subjects intravenously pre-operatively, upon admission to the ICU, then daily up to post-operative day 10 or ICU discharge, whichever occurs first.
All patients will receive an IV bolus of normal saline (equals to 40ml prepared solution) within 30min after induction of anesthesia via the central venous catheter. After termination of surgery, immediately after admission to the ICU, all patients will receive a second bolus of normal saline accordingly. Then on every further morning during ICU-stay, patients will receive an IV bolus of normal saline via central or peripheral venous access until death, discharge from ICU to the ward (treatment may continue in a step down or intermediate care unit), or for a maximum of 10 days.
Other Name: NaCl 0.9%
Active Comparator: sodium selenite
High-dose sodium-selenite will be administered to subjects intravenously:
1) pre-operatively (2000 ug); 2) upon admission to the ICU (2000 ug), 3) then daily (1000 ug) up to post-operative day 10 or ICU discharge, whichever occurs first.
Drug: sodium selenite
All subjects will receive an IV bolus of 2000µg selenium within 30min after induction of anesthesia via the central venous catheter. After termination of surgery, immediately after admission to the ICU, all patients will receive a second bolus of 2000µg selenium. Then on every further morning during ICU-stay, patients will receive an IV bolus of 1000µg selenium via central or peripheral venous access until death, discharge from ICU to the ward, or for a maximum of 10 days.
Other Name: selenium
- PODS free days + alive [ Time Frame: 30 Day ]Evaluate the PODS free days + alive as the primary outcome for the large-scale Phase III trial. We define PODS as the need for life-sustaining therapies (mechanical ventilation, vasopressor therapy, mechanical circulatory support, continuous renal replacement therapy, or intermittent hemodialysis).
- 30-Day Mortality [ Time Frame: 30 Day ]Mortality 30 days post-randomization.
- Hospital Acquired Infections [ Time Frame: 30 day ]To be evaluated up to 6 months post-randomization.
- Perioperative hemodynamic profile [ Time Frame: 6 months ]This includes: mean arterial blood pressure, cardiac power index, systemic vascular resistance, etc... To be assessed up to 6-months post-randomization.
- Cardiovascular Complications [ Time Frame: 6-months ]This includes: arrhythmias, cardiac arrest, infarction. To be assessed up to 6-months.
- Duration of Mechanical Ventilation [ Time Frame: 6-months ]To be assessed up to 6-months.
- Incidence of post-operative delirium [ Time Frame: 6-months ]Assessed by CAM-ICU score. To be assessed up to 6-months.
- ICU Length of stay [ Time Frame: 6-months ]To be assessed up to 6 months post-randomization.
- Hospital Re-admission Rates [ Time Frame: 6-months ]To be assessed up to 6-months post-randomization.
- Hospital Length of stay [ Time Frame: 6-months ]To be assessed up to 6 months post-randomization.
- 6-Month Survival [ Time Frame: 6-months ]To be assessed at 6 months post-randomization.
- Quality of Life [ Time Frame: 6-months ]Health related quality of life to be assessed up to 6-months post-randomization.
- Return to work [ Time Frame: 6-months ]Assessed using a questionnaire to determine the patient's ability to return to their pre-operative working capabilities. To be assessed up to 6 months post-randomization.
- Laboratory outcomes [ Time Frame: POD 10 ]
To be assessed up to post-operative day (POD) 10 in patients who consent to this optional blood work.
To assess the potential effects of supplementation on selenium levels, safety parameters and other mechanistic markers. Whole blood levels of selenium, selenoprotein P (Sel-P), antibodies against oxidized LDL, markers of inflammation (interleukin[IL]-6, IL-10, TNF alpha) and activity of glutathione-peroxidase (GPx) will be assessed to determine the efficacy of selenium supplementation in these patients.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02002247
|Contact: Daren K Heyland, MD||613-549-6666 ext firstname.lastname@example.org|
|Hamilton General Hospital||Recruiting|
|Hamilton, Ontario, Canada|
|Contact: Whitlock Richard, MD|
|London Health Sciences Centre||Recruiting|
|London, Ontario, Canada|
|Contact: Phil Jones, MD|
|University of Ottawa Heart Institute||Recruiting|
|Ottawa, Ontario, Canada|
|Contact: Bernard J McDonald, MD|
|Principal Investigator: Bernard J McDonald, MD|
|Sunnybrook Health Sciences Centre||Recruiting|
|Toronto, Ontario, Canada, M4N3M5|
|Principal Investigator: Stephen Fremes, MD|
|Principal Investigator: Robert Fowler, MD|
|St. Michael's Hospital||Recruiting|
|Toronto, Ontario, Canada|
|Contact: David Mazer, MD|
|Toronto General Hospital||Recruiting|
|Toronto, Ontario, Canada|
|Contact: Matteo Parotto, MD|
|Institut de cardiologie de Montreal||Recruiting|
|Montreal, Quebec, Canada, H1C1T8|
|Contact: Yoan Lamarche, MD|
|Principal Investigator: Yoan Lamarche, MD|
|Sir Mortimer B. Davis Jewish General Hospital||Recruiting|
|Montreal, Quebec, Canada, H3T 1E2|
|Contact: Matthew Cameron, MD|
|McGill University Health Centre||Recruiting|
|Montreal, Quebec, Canada|
|Contact: Roupen Hatzakorzian, MD|
|Montreal, Quebec, Canada|
|Contact: Yoan Lamarche, MD|
|Quebec City, Quebec, Canada|
|Contact: Siamak Mohammadi, MD|
|RWTH Aachen University Hospital||Recruiting|
|Aachen, Germany, 52074|
|Contact: Christian Stoppe, MD 0049-024108036575 email@example.com|
|Principal Investigator: Christian Stoppe, MD|
|Klinik und Poliklinik für Anästhesiologie und Operative Intensivmedizin Universitätsklinikum Bonn||Recruiting|
|Contact: Maria Wittman, MD|
|Frankfurt, Germany, 60590|
|Contact: Patrick Meybohm, MD : 069/ 6301 - 5998 firstname.lastname@example.org|
|Principal Investigator: Patrick Meybohm, MD|
|Klinik für Her- und Gefäßchirurgie Universitäts-Herzzentrum Freiburg||Recruiting|
|Contact: Georg Trummer, MD|
|Klinik für Herz-, Kinderherz- und Gefäßchirurgie UKGM Giessen||Recruiting|
|Contact: Bernd Niemann, MD|
|University Medical Center Schleswig-Holstein||Recruiting|
|Contact: Gunnar Elke, MD +49 431 5972991 email@example.com|
|Klinik und Poliklinik für Herz- und Thoraxchirurgie Uniklinik Köln||Recruiting|
|Contact: Oliver Liakopoulos, MD|
|Klinik für Anästhesiologie Universitätsmedizin Mainz||Recruiting|
|Contact: Rita Laufenberg, MD|
|Klinik für Anästhesiologie Klinikum der Universität München||Recruiting|
|Contact: Erich Kilger, MD|
|Klinik für Anästhesiologie, operative Intensivmedizin und Schmerztherapie Universitätsmedizin Münster, Zentralklinikum||Recruiting|
|Contact: Thomas Ermert, MD|
|Klinikum Oldenburg gGmbH Universitätsklinik für Anästhesiologie / Intensivmedizin / Notfallmedizin / Schmerztherapie||Recruiting|
|Contact: Malte Book, MD|
|Contact: Thomas Grote, MD|
|Klinik und Poliklinik für Anästhesiologie und Intensivtherapie Universitätsmedizin Rostock||Not yet recruiting|
|Contact: Frank Kletzin|
|Principal Investigator:||Daren K Heyland, MD||Queen's University|
|Principal Investigator:||Christian Stoppe, MD||RWTH Aachen University Hospital|
|Principal Investigator:||Bernard J McDonald, MD||Ottawa Heart Institute Research Corporation|